Osteonecrosis Treatment Market Increase in Research

Treatment of osteonecrosis

๐†๐ฅ๐จ๐›๐š๐ฅ ๐Ž๐ฌ๐ญ๐ž๐จ๐ง๐ž๐œ๐ซ๐จ๐ฌ๐ข๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ

Osteonecrosis is a disease in which bone cells collapse due to a lack of blood flow to the bones. It is also known as avascular necrosis, aseptic necrosis, or ischemic necrosis. Osteonecrosis most often develops in the hip bone (femur) or knees, but less often in the shoulder, wrist, ankle, hands, and feet. It can cause mild to severe pain and can lead to a micro-fracture. Osteonecrosis can be diagnosed using x-rays, CT scans, MRI scans, bone scans, and functional bone tests. Treatment for osteonecrosis targets symptoms and reduces pain through medication or surgery in extreme cases. According to the National Organization for Rare Diseases, osteonecrosis is one of the rare diseases, where less than one in 2,000 people is affected only by this disease. In 2017, Bone Therapeutics reported that approximately 170,000 patients suffered from osteonecrosis in Europe, the United States and Japan. Advances in stem cell-based osteonecrosis treatment, gene therapy, and treatment technologies are expected to propel the growth of the global osteonecrosis treatment market during the forecast period.

๐Ÿ๐จ๐ซ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐š๐ญ โ€“https://www.coherentmarketinsights.com/insight/request-sample/1490

๐†๐ฅ๐จ๐›๐š๐ฅ ๐Ž๐ฌ๐ญ๐ž๐จ๐ง๐ž๐œ๐ซ๐จ๐ฌ๐ข๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค

Advanced Therapy Drugs (ATMP) are a class of innovative therapies that include gene therapy, somatic cell therapy, and tissue engineered products, and their market introduction is expected to boost the development of the global market for the treatment of osteonecrosis. Osteonecrosis generally affects the young population and it will contribute significantly to the growth of the osteonecrosis treatment market. For example, according to the American College of Rheumatology, in 2017, approximately 10,000 to 20,000 people in the United States who suffered from osteonecrosis were between the ages of 20 and 50. Currently, the non-surgical treatment of osteonecrosis (medication) is symptomatic treatment that targets the symptoms and tries to cure the disease. Consequently, emerging players in the field of bone disease treatment are gaining momentum by introducing a gene regulation approach. Major market players like Enzo Biochem, Inc. and Bone Therapeutics are targeting gene regulation and processing of cell-based products, which is expected to increase the growth of the osteonecrosis treatment market. For example, PREOB manufactured by Bone Therapeutics, a cell-based drug derived from autologous bone marrow stem cells, has been approved in the United States and is currently in its third phase of development in Europe.

๐‡๐ž๐ซ๐ž ๐๐ƒ๐… ๐๐ซ๐จ๐œ๐ก๐ฎ๐ซ๐ž @ https://www.coherentmarketinsights.com/insight/request-pdf/1490

Although osteonecrosis is a rare disease, the global osteonecrosis treatment market is expected to experience tremendous growth, owing to the increasing prevalence of the causative agents of osteonecrosis. Side effects of various drugs taken during cancer, HIV / AIDS, osteoarthritis, osteoporosis or blood disorders or medical treatments such as chemotherapy, radiation therapy, high doses of steroids or organ transplants may increase the risk of osteonecrosis. In addition, a few interventions such as the Stanford University-sponsored project aim to assess osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI, which improves detection and allows tracking of transplanted bone marrow cells. . This intervention is in Phase IV clinical trial and is expected to complete the project during the forecast period, which in turn would propel the growth of the global osteonecrosis treatment market.

๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ

North America is expected to hold a dominant position in the global osteonecrosis treatment market during the forecast period, owing to the increase in the osteonecrosis prevalence pool and FDA approvals for de new treatment options in the region. According to the 2015 NCBI report, it is estimated that approximately 20,000 to 30,000 new patients are diagnosed with osteonecrosis each year in the United States. Furthermore, the Asia-Pacific market is expected to grow at a comparatively faster rate in the global osteonecrosis treatment market during the forecast period owing to increased development activities carried out by various key players in this region. For example, Bone Therapeutics and Asahi Kasei Corporation signed a license agreement in 2017 for the development and commercialization of PREOB in Japan.

๐Ž๐ฌ๐ญ๐ž๐จ๐ง๐ž๐œ๐ซ๐จ๐ฌ๐ข๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ โ€“ ๐Š๐ž๐ฒ ๐‚๐จ๐ฆ๐ฉ๐ž๐ญ๐ข๐ญ๐จ๐ซ๐ฌ

Major players involved in the global osteonecrosis treatment market include Bone Therapeutics, Enzo Biochem Inc., K-Stemcell Co. Ltd. hospitals. and many leading universities and institutes.

๐ญ๐ก๐ข๐ฌ ๐๐ซ๐ž๐ฆ๐ข๐ฎ๐ฆ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ โ€“ https://www.coherentmarketinsights.com/insight/buy-now/1490

๐”๐’:

Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837

๐”๐ฌ:

Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients of all backgrounds, from Fortune 500 companies to nonprofits and startups looking to enter the market. We excel in delivering unmatched actionable market insights across various industry verticals including Chemicals & Materials, Healthcare, Food & Beverage, Consumer Goods, Packaging, Semiconductors , software and services, telecommunications and automotive. We offer syndicated market intelligence reports, custom research solutions, and advisory services.

This version was posted on openPR.

Source link

About Chris Y. Camp

Check Also

Mother / daughter nurse practitioners guide children through cancer treatment, survival

Choose a topic Empower / Inspire October 29, 2021 3 minutes to read Source / โ€ฆ

Leave a Reply

Your email address will not be published. Required fields are marked *